Avid Bioservices News

Avid Bioservices Is Maintained at Outperform by RBC Capital

Avid Bioservices Is Maintained at Outperform by RBC Capital

Dow JonesMay 1 01:18

Royal Bank of Canada: Maintaining the Avid Bioservices (CDMO.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $7.00 to $8.00.

Royal Bank of Canada: Maintaining the Avid Bioservices (CDMO.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $7.00 to $8.00.

Zhitong FinanceMay 1 01:10

RBC Capital Maintains Outperform on Avid Bioservices, Raises Price Target to $8

RBC Capital analyst Sean Dodge maintains Avid Bioservices (NASDAQ:CDMO) with a Outperform and raises the price target from $7 to $8.

BenzingaMay 1 01:09

Avid Bioservices Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/30/2024 11.42% RBC Capital $7 → $8 Maintains Outperform 03/11/2024 67.13% Stephens & Co. $15 → $12 Main

BenzingaMay 1 01:07

Analysts' Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Decibel Cannabis Company (OtherDBCCF) and Avid Bioservices (CDMO)

TipRanksApr 30 20:40

Q3 2024 Avid Bioservices Inc Earnings Call

Yahoo FinanceApr 30 18:48

Analysts Offer Insights on Healthcare Companies: AIM ImmunoTech (AIM) and Avid Bioservices (CDMO)

TipRanksApr 30 18:40

Earnings Call Summary | Avid Bioservices(CDMO.US) Q3 2024 Earnings Conference

The following is a summary of the Avid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call Transcript:Financial Performance:Avid Bioservices saw a significant increase in revenues by over 30% in Q3 2024 co

Futu NewsApr 30 09:52 · Conference Call

Avid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call Transcript

Avid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call Transcript

Earnings Call TranscriptsApr 30 09:39

Avid Bioservices Q3 Financial Results Conference Call Announcement

TipRanksApr 25 18:13

Avid Bioservices Maintains FY24 Revenue Guidance Of $137M-$147M, Est $138.656M

Avid Bioservices Maintains FY24 Revenue Guidance Of $137M-$147M, Est $138.656M

BenzingaApr 25 05:40

Avid Bioservices Q3 2024 GAAP EPS $(0.09) Misses $(0.05) Estimate, Sales $33.800M Beat $33.452M Estimate

Avid Bioservices (NASDAQ:CDMO) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.05) by 80 percent. The company reported quarterly sales of $33.800 mil

BenzingaApr 25 05:39

Avid Bioservices 3Q Rev $33.8M >CDMO

Avid Bioservices 3Q Rev $33.8M >CDMO

Dow JonesApr 25 05:25

Avid Bioservices 3Q Loss/Shr 9c >CDMO

Avid Bioservices 3Q Loss/Shr 9c >CDMO

Dow JonesApr 25 05:25

Press Release: Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 -- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Recor

Dow JonesApr 25 05:25

Analysts' Top Healthcare Picks: Avid Bioservices (CDMO), LifeMD (LFMD)

TipRanksApr 16 20:40

Craig-Hallum Remains a Buy on Avid Bioservices (CDMO)

TipRanksApr 1 20:36

Avid Bioservices Announces Receipt of Deficiency Notice From Nasdaq Regarding Late Form 10-Q

TUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a notice (the

GlobeNewswireMar 20 19:00

Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages...

Stockhouse Mar 17 19:00

Avid Bioservices Is Maintained at Overweight by Stephens & Co.

Avid Bioservices Is Maintained at Overweight by Stephens & Co.

Dow JonesMar 11 23:10